Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy.

Jang WS, Kim LH, Yoon CY, Rha KH, Choi YD, Hong SJ, Ham WS.

PLoS One. 2016 Oct 7;11(10):e0164497. doi: 10.1371/journal.pone.0164497. eCollection 2016.

2.

A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancer.

Makarov DV, Sedlander E, Braithwaite RS, Sherman SE, Zeliadt S, Gross CP, Curnyn C, Shedlin M.

Implement Sci. 2016 Sep 2;11(1):118. doi: 10.1186/s13012-016-0484-5.

3.

Which better predicts mortality among older men, a prostate cancer (PCa) diagnosis or vulnerability on the Vulnerable Elders Survey (VES-13)? A retrospective cohort study.

Lowenstein LM, Mohile SG, Gil HH, Pandya C, Hemmerich J, Rodin M, Dale W.

J Geriatr Oncol. 2016 Nov;7(6):437-443. doi: 10.1016/j.jgo.2016.07.011. Epub 2016 Jul 30.

PMID:
27480793
4.

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.

Tonry CL, Leacy E, Raso C, Finn SP, Armstrong J, Pennington SR.

Diagnostics (Basel). 2016 Jul 18;6(3). pii: E27. doi: 10.3390/diagnostics6030027. Review.

5.

Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?

Nderitu P, Van Hemelrijck M, Ashworth M, Mathur R, Hull S, Dudek A, Chowdhury S.

BMJ Open. 2016 Jul 12;6(7):e011356. doi: 10.1136/bmjopen-2016-011356.

6.

Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy.

Hu Y, Kasivisvanathan V, Simmons LA, Clarkson MJ, Thompson SA, Shah TT, Ahmed HU, Punwani S, Hawkes DJ, Emberton M, Moore CM, Barratt DC.

IEEE Trans Biomed Eng. 2017 Apr;64(4):946-958. doi: 10.1109/TBME.2016.2582734. Epub 2016 Jun 21.

PMID:
27337710
7.

Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Oppenheimer DC, Weinberg EP, Hollenberg GM, Meyers SP.

J Clin Imaging Sci. 2016 Apr 29;6:18. doi: 10.4103/2156-7514.181494. eCollection 2016. Review.

8.

A hospital-based study of initial observation for low-risk prostate cancer and its predictors in the United States.

Maurice MJ, Zhu H, Abouassaly R.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E193-9. doi: 10.5489/cuaj.2606. Epub 2015 Apr 13.

9.

The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer.

Mustafa M, Delacroix S, Ward JF, Pisters L.

World J Surg Oncol. 2015 Dec 21;13:340. doi: 10.1186/s12957-015-0753-9.

10.

Appropriateness of Prostate Cancer Imaging among Veterans in a Delivery System without Incentives for Overutilization.

Makarov DV, Hu EY, Walter D, Braithwaite RS, Sherman S, Gold HT, Zhou XH, Gross CP, Zeliadt SB.

Health Serv Res. 2016 Jun;51(3):1021-51. doi: 10.1111/1475-6773.12395. Epub 2015 Sep 30.

PMID:
26423687
11.

A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype.

Zhu G, Liu Z, Epstein JI, Davis C, Christudass CS, Carter HB, Landis P, Zhang H, Chung JY, Hewitt SM, Miller MC, Veltri RW.

Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1864-72. doi: 10.1158/1055-9965.EPI-15-0496. Epub 2015 Sep 24.

12.

Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation.

Panebianco V, Barchetti F, Barentsz J, Ciardi A, Cornud F, Futterer J, Villeirs G.

Insights Imaging. 2015 Dec;6(6):611-30. doi: 10.1007/s13244-015-0426-9. Epub 2015 Sep 18.

13.

Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP).

Antwi SO, Steck SE, Su LJ, H├ębert JR, Zhang H, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L.

Prostate. 2015 Sep;75(13):1419-35. doi: 10.1002/pros.23025. Epub 2015 Jun 5.

14.

Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk.

Xu G, Wu J, Yao MH, Yao XD, Peng B, Wei Q, Xu HX, Wu R.

Int J Clin Exp Med. 2015 Feb 15;8(2):2562-9. eCollection 2015.

15.

Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.

Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, L'Esperance JO, Sterbis JR, Etzioni R, Porter CR.

Cancer. 2015 Jul 15;121(14):2465-73. doi: 10.1002/cncr.29370. Epub 2015 Apr 6.

16.

A New CT Prostate Segmentation for CT-Based HDR Brachytherapy.

Yang X, Rossi P, Ogunleye T, Jani AB, Curran WJ, Liu T.

Proc SPIE Int Soc Opt Eng. 2014;9036:90362K.

17.

Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW.

Eur Urol. 2015 Dec;68(6):1083-8. doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25.

18.
19.

Guideline of Guidelines: Imaging of Localized Prostate Cancer.

Wollin DA, Makarov DV.

BJU Int. 2015 Oct;116(4):526-30. doi: 10.1111/bju.13104. Epub 2015 Jun 6. No abstract available.

20.

Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy.

Yang X, Rossi P, Ogunleye T, Marcus DM, Jani AB, Mao H, Curran WJ, Liu T.

Med Phys. 2014 Nov;41(11):111915. doi: 10.1118/1.4897615.

Supplemental Content

Support Center